TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era
link : TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era

TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era

In Case You Missed It - TAG Pipeline Report HIV, TB, and HCV

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

The 2017 Pipeline Report

July 2017

HIV, TB, and HCV
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development
Written by Mike Frick, Annette Gaudino, Mark Harrington, Tim Horn, Richard Jefferys, Jeremiah Johnson, Erica Lessem, Marcus Low, and Lindsay McKenna

Begin here.....

Hepatitis C

HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era

Annette Gaudino

AbbVie, Gilead, Merck, and Janssen have presented data at international congresses on efficacy across the six major genotypes; in difficult-to-treat populations, including patients with genotype 3 and cirrhosis; and patients with advanced kidney disease. Gilead also recently received approval for previously untreated adolescents, and presented data on ongoing clinical trials in young children. It would not be hyperbole to state that science has solved chronic HCV infection for all but individuals with decompensated cirrhosis—yet another powerful argument for early treatment. It must be noted that, as historically has been the case, all clinical trial data is based on majority male patient populations, with few people of color, particularly African Americans, taking part in clinical trials....

Continue reading....

Updates On This Blog

Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir FDA Approved

On July 18, 2017 Gilead's VoseviTM (Sofosbuvir/Velpatasvir/Voxilaprevir) was FDA approved,

last month CHMP - the scientific committee of the European Medicines Agency adopted a positive opinion on the company’s marketing authorization application for Vosevi.

April 7, 2017
FDA Approves HCV Sovaldi and Harvoni For Children Ages 12 to 17

In this year's report:

July 2017

Introduction and Executive Summary
Mark Harrington

The Antiretroviral Pipeline
Tim Horn

Preventive Technologies:
Antiretroviral and Vaccine Development
Jeremiah Johnson & Richard Jefferys

Research Toward a Cure and Immune-Based and Gene Therapies
Richard Jefferys

The Tuberculosis Diagnostics Pipeline
Erica Lessem

The Tuberculosis Prevention Pipeline
Mike Frick

The Tuberculosis Treatment Pipeline:
A Breakthrough Year for the Treatment of XDR-TB
Marcus Low

The Tuberculosis Diagnostics and Treatment Pipeline for Children
Lindsay McKenna

HCV Pipeline: DAAs and Diagnostics in the Pangenotypic Era
Annette Gaudino

Thus articles TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era

that is all articles TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article TAG HCV Pipeline Report: DAAs and Diagnostics in the Pangenotypic Era the link address https://newsaninpiration.blogspot.com/2017/07/tag-hcv-pipeline-report-daas-and.html

Tweet

Subscribe to receive free email updates: